Results 51 to 60 of about 571,284 (260)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +1 more source

Pharmaceutical systematics: Description and preliminary investigation of an alternative method for structuring drug information

INNOVATIONS in Pharmacy, 2011
Objectives: To identify the 30 most common adverse drug events or reactions (ADE/ADRs) within the top 200 medications: (1) by raw incidence, (2) weighted by prescription volume, (3) and weighted by retail dollars.
Mary E. Kiersma, Aleda M. H. Chen, Kristin R. Villa, Brian M. Shepler, Matthew M. Murawski   +4 more
doaj   +1 more source

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi‐Center Phase‐III Randomized Clinical Trials

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier, Mark Zobeck, Adam J. Esbenshade, Christopher C. Dvorak, Lillian Sung, David Freyer, Sarah Alexander, Etan Orgel, Nicole J. Ullrich, Zach Prudowsky, Brian Fisher, Caitlin W. Elgarten   +11 more
wiley   +1 more source

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
BackgroundFaricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs ...
Chang-Zhu He, Qin Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He   +5 more
doaj   +1 more source

Nephrogenic Rests/Nephroblastomatosis in Patients With Unilateral Wilms Tumor Are Not Associated With an Increased Risk of Relapse: An Analysis of Patients Treated on the SIOP‐WT‐2001 Protocol in the SIOP‐UK‐CCLG and SIOP‐GPOH Studies (2001–2022)

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Nephrogenic rests (NRs) and nephroblastomatosis (NBM) are precursor lesions for development of Wilms tumor (WT). Their association with the risk of relapse has not been properly assessed, partly due to misunderstanding of their diagnostic criteria and terminology.
Gordan M. Vujanić, Rhoikos Furtwängler, Tanzina Chowdhury, Christian Vokuhl, Jenny Wegert, Norbert Graf   +5 more
wiley   +1 more source

Hemin coupled protein biomimetic nanozymes combining confinement effects for sensitive chemiluminescence immunoassay

ChemPhysMater
Nanozymes offer superior stability and resistance to deactivation while mimicking the catalytic activity of natural enzymes, thereby expanding their applications across various fields.
Tong Jiang, Yanan Lou, Jin Wang, Huan Wang, Yuyang Li, Hongmin Ma   +5 more
doaj   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Adverse events [PDF]

American Journal of Orthodontics and Dentofacial Orthopedics, 2017
  +5 more sources

Safety and risk control study of antibody preparation based on CiteSpace

Journal of Holistic Integrative Pharmacy
Objective: To analyze the hotspots, patterns, and distribution of research on the safety and risk of antibody preparations in the past 20 years. It also seeks to summarize the current status and trends of research on the safety and risk control of ...
Chanyuan Chen, Rong Wang, Yuanxuan Cai, Yuhang Zhao, Zherui Chen, Ke Li, Li Zhao, Rui Huang, Nooruldeen Riyadh Ibrahim, Xiaofang Shangguan   +9 more
doaj   +1 more source

Time to Diagnosis Among Children and Adolescents With Cancer in Québec, Canada: A Population‐Based Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely cancer diagnosis in children and adolescents is important to improving outcomes. We aimed to quantify time to diagnosis and assess variations by patient, demographic and system‐level factors. Procedure We conducted a population‐based study of individuals aged 0–19 years diagnosed with one of 12 cancers from 2010 to 2022 in ...
Callum Mullen, Ronald D. Barr, Erin Strumpf, Mariam El‐Zein, Eduardo L. Franco, Talía Malagón   +5 more
wiley   +1 more source